7.01.05 Cochlear Implant

Original Policy Date: March 5, 1986
Effective Date: May 1, 2020
Section: 7.0 Surgery
Page: Page 1 of 30

Policy Statement

Unilateral or bilateral cochlear implantation of a U.S. Food and Drug Administration (FDA)–approved cochlear implant may be considered medically necessary for patients who meet all of the following criteria:

- Patient’s age is 12 months or older
- Patient has bilateral severe-to-profound pre- or post-lingual (sensorineural) hearing loss, defined as a hearing threshold pure-tone average of 70 dB hearing loss or greater at 500 Hz, 1000 Hz, and 2000 Hz
- Patient has shown limited or no benefit from hearing aids

Replacement of internal and/or external components may be considered medically necessary for patients who meet either of the following:

- Patient has inadequate response to existing component(s) to the point of interfering with the individual’s activities of daily living
- The component(s) is/are no longer functional and cannot be repaired.

Cochlear implantation with a hybrid cochlear implant/hearing aid device that includes the hearing aid integrated into the external sound processor of the cochlear implant (e.g., the Nucleus® Hybrid™ L24 Cochlear Implant System) may be considered medically necessary for patients who meet all of the following criteria:

- Patient’s age is 18 years or older
- Bilateral severe-to-profound high-frequency sensorineural hearing loss with residual low-frequency hearing sensitivity
- Receive limited benefit from appropriately fit bilateral hearing aids
- Have all of the following hearing thresholds:
  - Low-frequency hearing thresholds no poorer than 60 dB hearing level up to and including 500 Hz (averaged over 125, 250, and 500 Hz) in the ear selected for implantation
  - Severe-to-profound mid- to high-frequency hearing loss (threshold average of 2000, 3000, and 4000 Hz greater than or equal to 75 dB hearing level) in the ear to be implanted
  - Moderately severe to profound mid- to high-frequency hearing loss (threshold average of 2000, 3000, and 4000 Hz greater than or equal to 60 dB hearing level) in the contralateral ear
  - Aided consonant-nucleus-consonant word recognition score from 10% to 60% in the ear to be implanted in the preoperative aided condition and in the contralateral ear will be equal to or better than that of the ear to be implanted but not more than 80% correct

The following is considered investigational:

- Cochlear implantation as a treatment for patients with unilateral hearing loss with or without tinnitus

The following is considered not medically necessary:

- Upgrades of an existing, functioning external system to achieve aesthetic improvement, such as smaller profile components or a switch from a body-worn, external sound processor to a behind-the-ear model
- Replacement of internal and/or external components solely for the purpose of upgrading to a system with advanced technology or to a next-generation device
Policy Guidelines

**Note:** Cochlear implants provide direct stimulation of the auditory nerve, bypassing the outer ear (conductive). Pure tone average means that each tone tested is only from one frequency (pure) and the various frequency results are averaged to get the final result. The threshold is the level at which the tone can be heard.

**Note:** A hybrid device combines a cochlear implant with a standard hearing aid in the same device. They are useful when low frequencies can be heard (less than 500 db) in the ear to be implanted, but not higher frequencies in either ear (greater than 2000 db); AND word recognition is poor even with hearing aids in the ear to be implanted; AND word recognition is also impaired in the ear not being implanted; AND that the non-implanted ear is not already better than 80%. A narrow window, where both ears are impaired, a little better in one but still not great, such that an implant in one ear and a hearing aid in the other would not be sufficient.

Bilateral cochlear implantation should be considered only when it has been determined that the alternative of unilateral cochlear implantation plus hearing aid in the contralateral ear will not result in a binaural benefit (i.e., in those patients with hearing loss of a magnitude where a hearing aid will not produce the required amplification).

In certain situations, implantation may be considered before 12 months of age. One scenario is post meningitis when cochlear ossification may preclude implantation. Another is in cases with a strong family history, because establishing a precise diagnosis is less uncertain.

Hearing loss is rated based on the threshold of hearing. Severe hearing loss is defined as a bilateral hearing threshold of 70 to 90 dB, and profound hearing loss is defined as a bilateral hearing threshold of 90 dB and above.

In adults, limited benefit from hearing aids is defined as scores of 50% correct or less in the ear to be implanted on tape-recorded sets of open-set sentence recognition. In children, limited benefit is defined as failure to develop basic auditory skills, and in older children, 30% or less correct on open-set tests.

A post cochlear implant rehabilitation program is necessary to achieve benefit from the cochlear implant. The rehabilitation program consists of 6 to 10 sessions that last approximately 2.5 hours each. The rehabilitation program includes development of skills in understanding running speech, recognition of consonants and vowels, and tests of speech perception ability.

Contraindications to cochlear implantation may include deafness due to lesions of the eighth cranial (acoustic) nerve, central auditory pathway, or brainstem; active or chronic infections of the external or middle ear; and mastoid cavity or tympanic membrane perforation. Cochlear ossification may prevent electrode insertion, and the absence of cochlear development as demonstrated on computed tomography scans remains an absolute contraindication.

**Coding**

CPT has a range of codes (92601-92609) to define a variety of postoperative evaluative and therapeutic services related to cochlear implants.

The following codes describe postoperative analysis and fitting of previously placed external devices, connection to cochlear implant, and programming of the stimulator:

- **92601:** Diagnostic analysis of cochlear implant, patient younger than 7 years of age; with programming
- **92603:** Diagnostic analysis of cochlear implant, age 7 years or older; with programming

The following codes describe subsequent sessions for measurement and adjustment of the external transmitter and reprogramming of the internal stimulator:
• **92602**: Diagnostic analysis of cochlear implant, patient younger than 7 years of age; subsequent reprogramming

• **92604**: Diagnostic analysis of cochlear implant, age 7 years or older; subsequent reprogramming

### Description

A cochlear implant is a device for treatment of severe-to-profound hearing loss in individuals who only receive limited benefit from amplification with hearing aids. A cochlear implant provides direct electrical stimulation to the auditory nerve, bypassing the usual transducer cells that are absent or nonfunctional in deaf cochlea.

### Related Policies

- Auditory Brainstem Implant
- Implantable Bone-Conduction and Bone-Anchored Hearing Aids
- Semi-Implantable and Fully Implantable Middle Ear Hearing Aids
- Treatment of Tinnitus

### Benefit Application

Benefit determinations should be based in all cases on the applicable contract language. To the extent there are any conflicts between these guidelines and the contract language, the contract language will control. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Some state or federal mandates (e.g., Federal Employee Program [FEP]) prohibits plans from denying Food and Drug Administration (FDA)-approved technologies as investigational. In these instances, plans may have to consider the coverage eligibility of FDA-approved technologies on the basis of medical necessity alone.

### Regulatory Status

Several cochlear implants are commercially available in the United States and are manufactured by Cochlear Americas, Advanced Bionics, and the MED-EL Corp. Over time, subsequent generations of the various components of the devices have been approved by the U.S. Food and Drug Administration (FDA), focusing on improved electrode design and speech-processing capabilities. Furthermore, smaller devices and the accumulating experience in children have resulted in broadening of the selection criteria to include children as young as 12 months. The labeled indications from the FDA for currently marketed implant devices are summarized in Table 1. FDA product code: MCM.

### Table 1. Cochlear Implant Systems Approved by the Food and Drug Administration

<table>
<thead>
<tr>
<th>Variables</th>
<th>Manufacturer and Currently Marketed Cochlear Implants</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adults ≥18 y</td>
<td>• Postlingual onset of severe-to-profound bilateral SNHL (≥70 dB)</td>
</tr>
<tr>
<td>PMA</td>
<td>• Pre-, peri-, or postlingual onset of bilateral SNHL, usually characterized by:</td>
</tr>
<tr>
<td>Predicate devices</td>
<td>• Severe-to-profound bilateral SNHL (≥70 dB)</td>
</tr>
<tr>
<td>PMA P960058</td>
<td>Med El® Maestro Combi 40+</td>
</tr>
<tr>
<td>P840024, P970051</td>
<td>Freedom with Contour</td>
</tr>
<tr>
<td>P000025</td>
<td>Clarion Multi-Strategy or HiFocus CII Bionic Ear (P940022)</td>
</tr>
<tr>
<td>Advanced Bionics®</td>
<td>Cochlear® Nucleus 22 and 24</td>
</tr>
<tr>
<td>HiResolution® Bionic Ear System (HiRes 90K)</td>
<td></td>
</tr>
</tbody>
</table>
### Variables

<table>
<thead>
<tr>
<th>Manufacturer and Currently Marketed Cochlear Implants</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Limited benefit from appropriately fitted hearing aids, defined as scoring ≤50% on a test of open-set HINT sentence recognition</td>
</tr>
<tr>
<td>• Moderate-to-profound HL in low frequencies; and</td>
</tr>
<tr>
<td>• Profound (≥90 dB) HL in mid-to-high speech frequencies</td>
</tr>
<tr>
<td>• Limited benefit from binaural hearing aids (≤50% sentence recognition in ear to be implanted)</td>
</tr>
<tr>
<td>• ≤40% correct HINT sentences with best-sided listening condition</td>
</tr>
</tbody>
</table>

### Children 12 mo to 17 y of age

- Profound bilateral SNHL (≥90 dB)
- Use of appropriately fitted hearing aids for at least 6 mo in children 2-17 y or at least 3 mo in children 12-23 mo
- Lack of benefit in children <4 y defined as a failure to reach developmentally appropriate auditory milestones (e.g., spontaneous response to name in quiet or to environmental sounds) measured using IT-MAIS or MAIS or <20% correct on a simple open-set word recognition test (MLNT) administered using monitored live voice (70 dB SPL)
- Lack of hearing aid benefit in children ≥4 y defined as scoring ≤12% on a difficult open-set word recognition test (PBK test) or ≤30% on an open-set sentence test (HINT for Children) administered using recorded materials in the sound field (70 dB SPL)
- Severe-to-profound bilateral SNHL
- MLNT scores ≤30% in best-aided condition in children 25 mo to 4 y 11 mo
- LNT scores ≤30% in best-aided condition in children 5 y to 17 y and 11 mo 12-24 mo
- Profound SNHL bilaterally
- Limited benefit from appropriate binaural hearing aids

### Children 25 mo to 17 y 11 mo

- Severe-to-profound bilateral SNHL
- MLNT scores ≤30% in best-aided condition in children 25 mo to 4 y 11 mo
- LNT scores ≤30% in best-aided condition in children 5 y to 17 y and 11 mo
- Profound SNHL bilaterally

### Children 12-24 mo

- Profound SNHL bilaterally
- Limited benefit from appropriate binaural hearing aids

### Children 12 mo to 18 y

- Profound sensorineural HL (≥90 dB)
- In younger children, little or no benefit is defined by lack of progress in the development of simple auditory skills with hearing aids over 3 to 6 mo
- In older children, lack of aided benefit is defined as ≤20% correct on the MLNT or LNT, depending on child’s cognitive ability and linguistic skills
- A 3- to 6-mo trial with hearing aids is required if not previously experienced

---

HINT: Hearing in Noise Test; HL: hearing loss; IT-MAIS: Infant-Toddler Meaningful Auditory Integration Scale; LNT: Lexical Neighborhood Test; MAIS: Meaningful Auditory Integration Scale; MLNT: Multisyllabic Lexical Neighborhood Test; PBK: Phonetically Balanced-Kindergarten; SNHL: sensorineural hearing loss; SPL: sound pressure level.

* The external Nucleus 5 sound processor is not a part of the recall. Advanced Bionics HiRes90K was voluntarily recalled in 2010 and given approval by the Food and Drug Administration for reentry to market the device in 2011. Cochlear voluntarily recalled the Nucleus CI500 range in 2011 for device malfunction in the CI512 implant.

In 2014, the Nucleus Hybrid™ L24 Cochlear Implant System (Cochlear Americas) was approved by the FDA through the premarket approval process. This system is a hybrid cochlear implant and hearing aid, with the hearing aid integrated into the external sound processor of the cochlear implant. It is indicated for unilateral use in patients ages 18 years and older who have residual low-frequency hearing sensitivity and severe-to-profound high-frequency sensorineural hearing loss, and who obtain limited benefit from an appropriately fit bilateral hearing aid. The electrode array inserted into the cochlea is shorter than conventional cochlear implants. According to the FDA’s premarket approval notification, labeled indications for the device include:

- Preoperative hearing in the range from “normal to moderate hearing loss [HL] in the low frequencies (thresholds no poorer than 60 dB HL up to and including 500 Hz)”
- Preoperative hearing with “severe to profound mid to high frequency hearing loss (threshold average of 2000, 3000, and 4000 Hz ≥75 dB HL) in the ear to be implanted”
- Preoperative hearing with “moderately severe to profound mid to high frequency hearing loss (threshold average of 2000, 3000, and 4000 Hz ≥60 dB HL) in the contralateral ear”
• “The CNC [Consonant-Nucleus-Consonant] word recognition score will be between 10% and 60%, inclusively, in the ear to be implanted in the preoperative aided condition and in the contralateral ear equal to or better than that of the ear to be implanted but not more than 80% correct.”

Other hybrid hearing devices have been developed but do not have FDA approval, including the Med El® EAS Hearing Implant System.

Although cochlear implants have typically been used unilaterally, interest in bilateral cochlear implantation has arisen in recent years. The proposed benefits of bilateral cochlear implants are to improve understanding of speech occurring in noisy environments and localization of sounds. Improvements in speech intelligibility with bilateral cochlear implants may occur through binaural summation (i.e., signal processing of sound input from 2 sides may provide a better representation of sound and allow the individual to separate noise from speech). Speech intelligibility and localization of sound or spatial hearing may also be improved with head shadow and squelch effects (i.e., the ear that is closest to the noise will receive it at a different frequency and with different intensity, allowing the individual to sort out the noise and identify the direction of sound). Bilateral cochlear implantation may be performed independently with separate implants and speech processors in each ear, or a single processor may be used. However, no single processor for bilateral cochlear implantation has been approved by the FDA for use in the United States. Also, single processors do not provide binaural benefit and may impair sound localization and increase the signal-to-noise ratio received by the cochlear implant.

### Rationale

**Background**
The basic structure of a cochlear implant includes both external and internal components. The external components include a microphone, an external sound processor, and an external transmitter. The internal components are implanted surgically and include an internal receiver implanted within the temporal bone and an electrode array that extends from the receiver into the cochlea through a surgically created opening in the round window of the middle ear.

Sounds picked up by the microphone are carried to the external sound processor, which transforms sound into coded signals that are then transmitted transcutaneously to the implanted internal receiver. The receiver converts the incoming signals into electrical impulses that are then conveyed to the electrode array, ultimately resulting in stimulation of the auditory nerve.

**Literature Review**
Evidence reviews assess the clinical evidence to determine whether the use of technology improves the net health outcome. Broadly defined, health outcomes are the length of life, quality of life, and ability to function—including benefits and harms. Every clinical condition has specific outcomes that are important to patients and managing the course of that condition. Validated outcome measures are necessary to ascertain whether a condition improves or worsens; and whether the magnitude of that change is clinically significant. The net health outcome is a balance of benefits and harms.

To assess whether the evidence is sufficient to draw conclusions about the net health outcome of technology, 2 domains are examined: the relevance, and quality and credibility. To be relevant, studies must represent one or more intended clinical use of the technology in the intended population and compare an effective and appropriate alternative at a comparable intensity. For some conditions, the alternative will be supportive care or surveillance. The quality and credibility of the evidence depend on study design and conduct, minimizing bias and confounding that can generate incorrect findings. The randomized controlled trial (RCT) is preferred to assess efficacy; however, in some circumstances, nonrandomized studies may be adequate. RCTs are rarely large enough or long enough to capture less common adverse
events and long-term effects. Other types of studies can be used for these purposes and to assess generalizability to broader clinical populations and settings of clinical practice. Unless otherwise noted, this evidence review refers to traditional cochlear implants (i.e., not hybrid cochlear implant/hearing aid systems [e.g., the Nucleus Hybrid L24 Cochlear Implant System]).

**Cochlear Implantation for Bilateral Sensorineural Hearing Loss**

**Clinical Context and Therapy Purpose**

The purpose of cochlear implants is to provide a treatment option that is an alternative to or an improvement on existing therapies, such as best-aided hearing, in patients with bilateral sensorineural hearing loss.

Contraindications to cochlear implantation may include deafness due to lesions of the eighth cranial (acoustic) nerve, central auditory pathway, or brainstem; active or chronic infections of the external or middle ear; and mastoid cavity or tympanic membrane perforation. Cochlear ossification may prevent electrode insertion, and the absence of cochlear development as demonstrated on computed tomography scans remains an absolute contraindication.

The question addressed in this evidence review is: Does the use of a cochlear implant improve the net health outcome for patients with bilateral hearing loss?

The following PICO was used to select literature to inform this review.

**Patients**

The relevant population of interest is individuals with bilateral sensorineural hearing loss.

**Interventions**

The therapy being considered is the cochlear implant, which has both external and internal components. The external components include a microphone, an external sound processor, and an external transmitter. The internal components are implanted surgically and include an internal receiver implanted within the temporal bone and an electrode array that extends from the receiver into the cochlea through a surgically created opening in the round window of the middle ear.

Patients with bilateral sensorineural hearing loss are actively managed by otolaryngologists, audiologists, and primary care providers in an outpatient clinical setting.

**Comparators**

Comparators of interest include best-aided hearing.

**Outcomes**

The general outcomes of interest are symptoms, functional outcomes, treatment-related mortality, and treatment-related morbidity.

The existing literature evaluating cochlear implant(s) as a treatment for bilateral sensorineural hearing loss has varying lengths of follow-up, ranging from 6 months. While studies described below all reported at least one outcome of interest, longer follow-up was necessary to fully observe outcomes. Therefore, 1-year of follow-up is considered necessary to demonstrate efficacy.

**Study Selection Criteria**

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
c. To assess longer-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
d. Studies with duplicative or overlapping populations were excluded.

**Cochlear Implantation: Unilateral Stimulation**

Cochlear implants are recognized as an effective treatment of sensorineural deafness, as noted in a 1995 National Institutes of Health Consensus Development Conference, which offered the following conclusions:

“Cochlear implantation improves communication ability in most adults with severe to profound deafness and frequently leads to positive psychological and social benefits as well.”

“Prelingually deafened adults may also be suitable for implantation, although these candidates must be counseled regarding realistic expectations. Existing data indicate that these individuals achieve minimal improvement in speech recognition skills.

However, other basic benefits, such as improved sound awareness, may provide psychological satisfaction and meet safety needs.”

“...training and educational intervention are fundamental for optimal postimplant benefit.”

The effectiveness of cochlear implants has been evaluated in several systematic reviews and technology assessments, both from the United States and abroad. Bond et al. (2009) authored a technology assessment to investigate the clinical and cost-effectiveness of unilateral cochlear implants (using or not using hearing aids) and bilateral cochlear implants compared with a single cochlear implant (unilateral or unilateral plus hearing aids) for severely to profoundly deaf children and adults.3 The clinical effectiveness review included 33 articles (1513 deaf children; 1379 adults), 2 of which were RCTs. They defined 62 different outcome measures, and overall evidence was of moderate-to-poor quality. Reviewers concluded: “Unilateral cochlear implantation is safe and effective for adults and children and likely to be cost-effective in profoundly deaf adults and profoundly and prelingually deaf children.”

Gaylor et al. (2013) published an updated technology assessment for the Agency for Healthcare Research and Quality.4 Sixteen (of 42) studies published through May 2012 evaluated unilateral cochlear implants. Most unilateral implant studies showed statistically significant improvement in mean speech scores, as measured by open-set sentence or multisyllable word tests; meta-analysis of 4 studies revealed significant improvements in cochlear implant relevant quality of life after unilateral implantation (standard mean difference, 1.71; 95% confidence interval [CI], 1.15 to 2.27). However, these studies varied in design, and considerable heterogeneity was observed across studies.

**Cochlear Implantation: Bilateral Stimulation**

While the use of unilateral cochlear implants in patients with severe-to-profound hearing loss has become a well-established intervention, bilateral cochlear implantation is becoming more common. Many publications have reported slight-to-modest improvements in sound localization and speech intelligibility with bilateral cochlear implants, especially with noisy backgrounds but not necessarily in quiet environments. When reported, the combined use of binaural stimulation improved hearing by a few decibels or percentage points.

In a meta-analysis, McRackan et al. (2018) determined the impact of cochlear implantation on quality of life and determined the correlation. From 14 articles with 679 cochlear implant patients who met the inclusion criteria, pooled analyses of all hearing-specific quality of life measures revealed a very strong improvement in quality of life after cochlear implantation (SMD=51.77).5 Subset analysis of cochlear implant-specific quality of life measures also showed very strong improvement (SMD=51.69). Thirteen articles with 715 patients met the criteria to evaluate...
associations between quality of life and speech recognition. Pooled analyses showed a low positive correlation between hearing-specific quality of life and word recognition in quiet (r=0.213), sentence recognition in quiet (r=0.241), and sentence recognition in noise (r=0.238). Subset analysis of cochlear implant-specific quality of life showed similarly low positive correlations with word recognition in quiet (r=0.213), word recognition in noise (r=0.241), and sentence recognition in noise (r=0.255) between quality of life and speech recognition ability. Using hearing-specific and cochlear implant-specific measures of quality of life, patients report significantly improved quality of life after cochlear implantation. This study is limited in that widely used clinical measures of speech recognition are poor predictors of patient-reported quality of life with cochlear implants.

In another meta-analysis, McRackan et al. (2018) aimed to determine the change in general health-related quality of life (HRQOL) after cochlear implantation and association with speech recognition. Twenty-two articles met criteria for meta-analysis of HRQOL improvement, but 15 (65%) were excluded due to incomplete statistical reporting. From the 7 articles with 274 cochlear implant patients that met inclusion criteria, pooled analyses showed a medium positive effect of cochlear implantation on HRQOL (SMD=0.79). Subset analysis of the Health Utilities Index 3 measure showed a large effect (SMD=0.84). Nine articles with 550 cochlear implant patients met inclusion criteria for meta-analysis of correlations between non-disease specific patient-reported outcome measures and speech recognition after cochlear implantation (word recognition in quiet [r=0.35], sentence recognition in quiet [r=0.40], and sentence recognition in noise [r=0.32]). Some limitations are, though regularly used, HRQOL measures are not intended to measure nor do they accurately reflect the complex difficulties facing cochlear implant patients. Only a medium positive effect of cochlear implantation on HRQOL was observed along with a low correlation between non-disease specific patient-reported outcome measures and speech recognition. The use of such instruments in this population may underestimate the benefit of cochlear implantation.

Crathorne et al. (2012) published a systematic review. The objective was to evaluate the clinical and cost-effectiveness of bilateral multichannel cochlear implants compared with unilateral cochlear implantation alone or in conjunction with an acoustic hearing aid in adults with severe-to-profound hearing loss. A literature search was updated through January 2012. Nineteen studies conducted in the United States and Europe were included. The review included 2 RCTs with waiting-list controls, 10 studies with prospective pre/post repeated-measure or cohort designs, 6 cross-sectional studies, and economic evaluation. All studies compared bilateral with unilateral implantation, and 2 compared bilateral implants with a unilateral implant plus acoustic hearing aid. The studies selected were of moderate-to-poor quality, including both RCTs. Meta-analyses could not be performed due to heterogeneity among studies in outcome measures and study designs. However, all studies reported that bilateral cochlear implants improved hearing and speech perception. One RCT found a significant binaural benefit over the first ear alone for speech and noise from the front (12.6%, p<0.001) and when noise was ipsilateral to the first ear (21% p<0.001); another RCT found a significant benefit for spatial hearing at 3 months post implantation compared with preimplantation (mean difference, 1.46; p<0.01). Quality of life results varied, showing bilateral implantation might improve quality of life in the absence of worsening tinnitus.

The Gaylor Agency for Healthcare Research and Quality assessment (previously reported) showed improvement across 13 studies in communication-related outcomes with bilateral implantation compared with unilateral implantation and additional improvements in sound localization compared with unilateral device use or implantation only. The risk of bias varied from medium to high across studies. Based on results from at least 2 studies, quality of life outcomes varied across tests after bilateral implantation; meta-analysis was not performed because of heterogeneity in designs across studies.

Since the publication of the systematic reviews described above, additional comparative studies and case series have reported on outcomes after bilateral cochlear implantation. For
example, in a 2016 prospective observational study including 113 patients with postlingual hearing loss, of whom 50 were treated with cochlear implants and 63 with hearing aids, cochlear implant recipients’ depression scores improved from preimplantation to 12 months posttreatment (Geriatric Depression Scale score improvement, 31% [95% CI, 10% to 47%]).

The van Zon et al. (2016) prospective study focused on tinnitus perception conducted as a part of a multicenter RCT comparing unilateral with bilateral cochlear implantation in patients who had severe bilateral sensorineural hearing loss. This analysis included 38 adults enrolled from 2010 to 2012 and randomized to simultaneous bilateral or unilateral cochlear implants. At 1 year, postimplantation, both unilaterally and bilaterally implanted patients had significant decreases in score on the Tinnitus Handicap Inventory (THI; a validated scale), with a change in score from 8 to 2 (p = 0.03) and from 22 to 12 (p = 0.04) for unilaterally and bilaterally implanted patients, respectively. Bilaterally implanted patients had a significant decrease in Tinnitus Questionnaire score (change in score, 20 to 9; p = 0.04).

**Cochlear Implantation in Pediatrics**

Similar to the adult population, the evidence related to the use of cochlear implants in children has been evaluated in several systematic reviews and technology assessments.

The Bond et al. (2009) technology assessment on cochlear implants made the following observations regarding cochlear implantation in children: All studies in children that compared 1 cochlear implant with nontecnologic support or an acoustic hearing aid reported gains on all outcome measures. Weak evidence showed greater gain from earlier implantation (before starting school).

In a review, Bond et al. (2009) identified 15 studies that met their inclusion criteria addressing cochlear implantation in children; all were methodologically weak and too heterogeneous to perform a meta-analysis. However, reviewers concluded that there was sufficient, consistent evidence demonstrating positive benefits with unilateral cochlear implants in severely to profoundly hearing-impaired children compared with acoustic hearing aids or no hearing support.

Baron et al. (2018) published the results of a single-center, retrospective review of 109 children and adolescents who received a second, sequential cochlear implant between 2008 and 2016. Inclusion criteria included <20 years at first cochlear implant, and minimum 12 years follow-up after second cochlear implant. Subjects were evaluated at baseline using tests for speech intelligibility and performance, auditory performance, and word and sentence recognition in silence and in noise. Patients were divided into 2 groups according to intercochlear implant interval: <3 years (Early Group), versus ≥ 3 years (Late Group); and into 2 groups according to initial performance with the first cochlear implant: word recognition <85% (Weak Group), versus ≥ 85% (Strong Group). On the Categories of Auditory Performance (CAP) scale, 28.1% of patients showed improvement at 3 months post-second cochlear implant, 47% at 12 months, and 51.9% at 24 months. Progression in CAP score between first cochlear implant and 3 months, 12 months, and 24 months post-second cochlear implant was significant (P < 0.05). On the Speech Intelligibility Rating (SIR) scale, 33.7% of patients showed improvement at 3 months, 45.4% at 12 months, and 52.6% at 24 months (P < 0.05). On word recognition, 47.4% of patients showed improvement at 3 months, 50.8% at 12 months, and 55% at 24 months (P < 0.05). On sentence recognition in silence, 66.6% of patients showed improvement at 3 months, 61.2% at 12 months, and 60.6% at 24 months (P < 0.05). Progression on sentence recognition in noise, on the other hand, was not significant (P = 0.55). In the Early group, CAP score improved in 44.4% of patients at 3 months, 72.4% at 12 months and 76.1% at 24 months (P < 0.05). In the Late group, progression was not significant at 3 months (P = 1) or 12 months (P = 0.06) but was significant at 24 months (P < 0.05). In the Early group, SIR score improved in 49.1% of patients at 3 months, 63.0% at 12 months and 72.1% at 24 months. In the Late group, SIR score improved in 14.3% of patients at 3 months, 23.3% at 12 months, and 27.3% at 24 months. Improvement was significant in both groups at 3 months, 12 months, and 24 months (P < 0.05). The following are some biases and limitations: (1) subjects’ ages advance over the study period. Audiometric and speech-
therapy tests are age-adapted, and were not necessarily the same at the various assessment time points; tests for older subjects are correspondingly more “difficult”, so that speech therapy scores at 1-year post-second cochlear implant might be better than at 2 years, due to the nature of the respective tests. This biases assessment of individual progression over time. Patients were implanted between 1.2 and 24 years of age. Speech therapy tests at 3 months, 12 months, and 24 months thus differed between younger and older patients, introducing an inter-individual bias. (2) certain factors were not taken into account, like socioeconomic level, parental investment in the project, or associated behavioral, cognitive, psychomotor or sensory disorders, although these strongly impact cochlear implant results. They are, however, difficult to quantify, being subjective.

**Cochlear Implant Timing in Pediatrics**

The optimal timing of cochlear implantation in children is of particular interest, given the strong associations between hearing and language development. As reported by Sharma and Dorman (2006), central auditory pathways are “maximally plastic” for about 3.5 years, making a case for earlier cochlear implantation of children with hearing impairment. Stimulation delivered before about 3.5 years of age results in auditory evoked potentials that reach normal values in 3 to 6 months.

Forli et al. (2011) conducted a systematic review of 49 studies on cochlear implant effectiveness in children that addressed the impact of age of implantation on outcomes. Heterogeneity of studies precluded meta-analysis. Early implantation was examined in 22 studies, but few studies compared outcomes of implantations performed before 1 year of age with implantations performed after 1 year of age. Studies suggested improvements in hearing and communicative outcomes in children receiving implants before 1 year of age, although it is uncertain whether these improvements were related to the duration of cochlear implant usage or age of implantation. However, reviewers noted hearing outcomes have been shown to be significantly inferior in patients implanted after 24 to 36 months. Finally, 7 studies were reviewed that examined cochlear implant outcomes in children with associated disabilities. In this population, cochlear implant outcomes were inferior and occurred more slowly but were considered to be beneficial.

As noted, the 1995 National Institutes of Health Consensus Development Conference concluded cochlear implants are recognized as an effective treatment of sensorineural deafness. This conference offered the following conclusions regarding cochlear implantation in children:

- Cochlear implantation has variable results in children. Benefits are not realized immediately but rather manifest over time, with some children continuing to show improvement over several years.
- Cochlear implants in children under 2 years old are complicated by the inability to perform detailed assessment of hearing and functional communication. However, a younger age of implantation may limit the negative consequences of auditory deprivation and may allow more efficient acquisition of speech and language. Some children with postmeningitis hearing loss under the age of 2 years have received an implant due to the risk of new bone formation associated with meningitis, which may preclude a cochlear implant at a later date.

Studies published since the systematic reviews above have suggested that cochlear implant removal and reimplantation (due to device malfunction or medical/surgical complications) in children is not associated with worsened hearing outcomes.

**Specific Indications for Cochlear Implantation in Pediatrics**

Several systematic reviews have evaluated outcomes after cochlear implantation for specific causes of deafness and in subgroups of pediatric patients. In 2011, a systematic review of 38 studies, Black et al. sought to identify prognostic factors for cochlear implantation in pediatric patients. A quantitative meta-analysis was not performed due to study heterogeneity.
However, 4 prognostic factors—age at implantation, inner ear malformations, meningitis, and connexin 26 (a genetic cause of hearing loss)—consistently influenced hearing outcomes. Pakdaman et al. (2012) conducted a systematic review of cochlear implants in children with cochleovestibular anomalies. Anomalies included inner ear dysplasia such as large vestibular aqueduct and anomalous facial nerve anatomy. Twenty-two studies were reviewed (total N=311 patients). Reviewers found implantation surgery was more difficult and speech perception was poorer in patients with severe inner ear dysplasia. Heterogeneity across studies limited interpretation of these findings.

**Auditory Neuropathy Spectrum Disorder**

In a systematic review, Fernandes et al. (2015) evaluated 18 published studies and 2 dissertations that reported hearing performance outcomes for children with auditory neuropathy spectrum disorder (ANSD) and cochlear implants. Studies included 4 nonrandomized controlled studies considered high quality, 5 RCTs considered low quality, and 10 clinical outcome studies. Most studies (n=14) compared the speech perception in children who had ANSD and cochlear implants to the speech perception in children who had sensorineural hearing loss and cochlear implants. Most of these studies concluded that children with ANSD and cochlear implants developed hearing skills similar to those with sensorineural hearing loss and cochlear implants; however, these types of studies do not permit comparisons across outcomes between ANSD patients treated with cochlear implants and those treated with usual care.

**Cochlear Implantation in Infants Younger Than 12 Months**

While currently available cochlear implants are labeled by the U.S. Food and Drug Administration (FDA) for use in children older than 12 months of age, earlier diagnosis of congenital hearing loss with universal hearing screening has prompted interest in cochlear implantation in children younger than 12 months old.

Vlastarakos et al. (2010) conducted a systematic review of studies on bilateral cochlear implantation in 125 children implanted before age 1. For this off-label indication, reviewers noted follow-up times ranged from a median duration of 6 to 12 months and, while results seemed to indicate accelerated rates of improvement in implanted infants, the evidence available was limited and of poor quality.

A number of small studies from outside the United States have reported on cochlear implants in infants younger than 12 months old. For example, in a study from Australia, Ching et al. (2009) published an interim report on early language outcomes among 16 children implanted before 12 months of age, compared with 23 who were implanted after 12 months of age (specific timing implantation was not provided). The results demonstrated that children who received an implant before 12 months of age developed normal language skills at a rate comparable with normal-hearing children, while those implanted later performed at 2 standard deviations (SD) below normal. Reviewers noted that these results were preliminary, because of the need to examine the effect of multiple factors on language outcomes and the rate of language development.

Similarly, in a study from Italy, Colletti et al. (2011) reported on 10-year results among 19 infants with cochlear implants received between the ages of 2 and 11 months (early implantation group) compared with 21 children implanted between the ages of 12 and 23 months and 33 children implanted between the ages of 24 and 35 months. Within the first 6 months postimplantation, there were no significant differences among groups in Category of Auditory Performance testing, but patients in the infant group had greater improvements than older children at the 12- and 36-month testing.

A more recent (2016) prospective study of 28 children with profound sensorineural hearing loss who were implanted early with cochlear implants (mean age at device activation, 13.3 months) reported that these children had social and conversational skills in the range of normal-hearing peers 1 year after device activation.
Cochlear Implantation in Children: Bilateral Stimulation

In a systematic review, Lammers et al. (2014) compared the evidence on the effectiveness of bilateral cochlear implantation with that for unilateral implantation among children with sensorineural hearing loss. Reviewers identified 21 studies that evaluated bilateral cochlear implantation in children, with no RCTs identified. Due to the limited number of studies, heterogeneity in outcomes and comparison groups, and high-risk for bias in the studies, reviewers could not perform pooled statistical analyses, so a best-evidence synthesis was performed. The best-evidence synthesis demonstrated that there is consistent evidence indicating the benefit of bilateral implantation for sound localization. One study demonstrated improvements in language development, although other studies found no significant improvements. Reviewers noted that the currently available evidence consisted solely of cohort studies that compared a bilaterally implanted group with a unilaterally implanted control group, with only 1 study providing a clear description of matching techniques to reduce bias.

Several publications not included in the Lammers et al. (2014) systematic review have evaluated bilateral cochlear implants in children. These studies, ranging in size from 91 to 961 patients, have generally reported improved speech outcomes with bilateral implantation, compared with unilateral implantation. In another retrospective case series (2013) of 73 children and adolescents who underwent sequential bilateral cochlear implantation with a long (>5 year) interval between implants, performance on the second implanted side was worse than the primary implanted side, with outcomes significantly associated with the interimplant interval.

Section Summary: Cochlear Implantation for Bilateral Sensorineural Hearing Loss

Multiple trials of cochlear implantation in patients with bilateral sensorineural hearing loss, although in varying patient populations, have consistently demonstrated improvements in speech recognition in noise and improved sound localization.

Cochlear Implantation for Unilateral Sensorineural Hearing Loss

Clinical Context and Therapy Purpose

The purpose of cochlear implant(s) is to provide a treatment option that is an alternative to or an improvement on existing therapies, such as best-aided hearing, in patients with unilateral sensorineural hearing loss.

Contraindications to cochlear implantation may include deafness due to lesions of the eighth cranial (acoustic) nerve, central auditory pathway, or brainstem; active or chronic infections of the external or middle ear; and mastoid cavity or tympanic membrane perforation. Cochlear ossification may prevent electrode insertion, and the absence of cochlear development as demonstrated on computed tomography scans remains an absolute contraindication.

The question addressed in this evidence review is: Does the use of a cochlear implant improve the net health outcome for patients with unilateral hearing loss?

The following PICO was used to select literature to inform this review.

Patients
The relevant population of interest is individuals with unilateral sensorineural hearing loss.

Interventions
The therapy being considered is cochlear implant(s).

Patients with unilateral sensorineural hearing loss are actively managed by otolaryngologists, audiologists, and primary care providers in an outpatient clinical setting.

Comparators
Comparators of interest include best-aided hearing.
Outcomes
The general outcomes of interest are symptoms, functional outcomes, treatment-related mortality, and treatment-related morbidity.

The existing literature evaluating cochlear implant(s) as a treatment for unilateral sensorineural hearing loss has varying lengths of follow-up, ranging from 3-months to 6-months. While studies described below all reported at least one outcome of interest, longer follow-up was necessary to fully observe outcomes. Therefore, 6-months of follow-up is considered necessary to demonstrate efficacy.

Study Selection Criteria
Methodologically credible studies were selected using the following principles:

a. To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
b. In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
c. To assess longer-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
d. Studies with duplicative or overlapping populations were excluded.

As noted, a number of potential benefits to binaural hearing exist, including binaural summation, which permits improved signal detection threshold, and sound localization. The potential benefits from binaural hearing have prompted interest in cochlear implantation for patients with unilateral hearing loss.

Systematic Reviews
Van Zon et al. (2015) published a systematic review of studies evaluating cochlear implantation for single-sided deafness or asymmetric hearing loss.28 Reviewers assessed 15 studies, 9 of which (n=112 patients) were considered of sufficient quality to be included in data review. Reviewers identified no high-quality studies of cochlear implantation in this population. Data were not pooled for meta-analysis due to high between-study heterogeneity, but reviewers concluded that studies generally reported improvements in sound localization, quality of life scores, and tinnitus after cochlear implantation, with varying results for speech perception in noise.

Nonrandomized Trials
Buss et al. (2018) published the results of an FDA clinical trial that investigated the potential benefit of cochlear implant for use in adult patients with moderate-to-profound unilateral sensorineural hearing loss and normal to near-normal hearing on the other side.29 The study population was 20 cochlear implant recipients with 1 normal or near-normal ear and the other met criterion for cochlear implantation. All subjects received a MED-EL standard electrode array, with a full insertion based on surgeon report. They were fitted with an OPUS 2 speech processor. This group was compared to 20 normal-hearing persons (control group) that were age-matched. Outcome measures included: sound localization on the horizontal plane; word recognition in quiet with the cochlear implant alone, and masked sentence recognition when the masker was presented to the front or the side of normal or near-normal hearing. The follow-up period was 12-months. While the majority of cochlear implant recipients with 1 normal or near-normal ear and the other met criterion for cochlear implantation. All subjects received a MED-EL standard electrode array, with a full insertion based on surgeon report. They were fitted with an OPUS 2 speech processor. This group was compared to 20 normal-hearing persons (control group) that were age-matched. Outcome measures included: sound localization on the horizontal plane; word recognition in quiet with the cochlear implant alone, and masked sentence recognition when the masker was presented to the front or the side of normal or near-normal hearing. The follow-up period was 12-months. While the majority of cochlear implant recipients had at least 1 threshold ≤ 80 dB prior to implantation, only 3 subjects had these thresholds after surgery. For cochlear implant recipients, scores on consonant-nucleus-consonant (CNC) words in quiet in the impaired ear rose an average of 4% (0-24%) at the postoperative test to a mean of 55% correct (10%-84%) with the cochlear implant alone at the 12-month test interval.

Dillon et al. (2019) published a clinical update reporting on the prevalence of low-frequency hearing preservation with the use of standard long electrode arrays (MED-EL Corporation) in a subset of 25 patients (12 with unilateral hearing loss) from earlier cohorts.30 Unaided hearing thresholds at 125 Hz were compared between the preoperative and initial activation intervals to
assess the change in low-frequency hearing. At activation, a significant elevation in the unaided hearing thresholds at 125 Hz was noted among a sample of 24 patients (p<0.001), with the majority of subjects (n=16) demonstrating no response to stimulus. The remaining 9 participants maintained an unaided low-frequency hearing threshold of ≤ 95 dB, and 5/9 participants met the fitting criterion of ≤ 80 dB for electric-acoustic stimulation (EAS) at initial activation. An additional 3 participants demonstrated improvement in unaided low-frequency hearing thresholds at latter monitoring intervals. It is uncertain whether identifying patients with preservation of low-frequency hearing can help predict individuals that may benefit from EAS versus standard cochlear implants.

Galvin III et al. (2019) reported data from an FDA approved study of cochlear implantation in 10 patients with single-sided deafness (SSD).31 Patients were implanted with the MED-EL Concerto Flex 28 device. Speech perception in quiet and noise, localization, and tinnitus severity were measured prior to implantation at 1, 3, and 6 months post activation. Performance was assessed with both ears (binaural), with the implanted ear alone, and the normal hearing alone. No patient had previous experience with contralateral routing of signal or bone conduction device system. Mean improvement for CNC word recognition versus baseline was 66.8% 76.0% and 84.0% at 1, 3, and 6 months postactivation, respectively. The normal hearing ear performed significantly better compared to the implanted ear for all outcome measures at all intervals (p<0.05). Audiological performance of the implanted ear at 1, 3, and 6 months postactivation was significantly better compared to baseline (p<0.05), with no significant difference across postactivation intervals (p>0.05). The change in root mean square error in localization with binaural listening postactivation reduced by 6.7, 7.6, and 11.5 degrees at 1, 3, and 6 months postactivation. Binaural performance was significantly improved compared to the normal hearing ear alone at all postactivation time intervals (p<0.05). Tinnitus visual analog scale (VAS) scores significantly decreased with the implant on at all postactivation time intervals (p<0.05). Significant improvements in Speech, Spatial, and Quality of Hearing Scale questionnaire (SSQ) scores were reported for the Speech (p=0.003), Spatial (p<0.001), and Quality (p=0.034) subtests. Global scores were not reported. Adverse events were reported in 5/10 participants, including facial nerve stimulation, periorbital edema, mild postoperative balance disturbance, postauricular pain, and unresolved taste disturbance. The study is limited by small sample size.

Peter et al. (2019) published the results of a Swiss multicenter study assessing cochlear implantation for use in adult patients in post-lingual SSD, defined as a hearing loss of 70 dB hearing level (HL) in the mean thresholds of 0.5, 1, 2, and 4 kHz in the affected ear, and 25 dB HL or better in the frequencies from 125 to 2 kHz and 35 dB HL or better from 4 to 8 kHz in the normally hearing contralateral ear.32 A total of 10 patients were evaluated. Two-year post-implantation, 90% of patients used their implant regularly for an average of more than 11 hours per day. Twelve months postactivation, speech from the front and noise at the healthy ear achieved a 2.7 dB improvement (p=0.0029). Speech to the implanted ear and noise from the front achieved a 1.5 dB improvement (p=0.018). The mean sound localization error of all participants was improved by 10.2 degrees (p=0.030) at 12 months postactivation. One participant experienced a loss in low-frequency residual hearing from surgery, resulting in poorer localization performance after surgery with an increased error of 11.3 degrees. Tinnitus severity decreased significantly 12 months postactivation from 41.2 points (SD 26.5) preoperatively to 23.0 points (SD 17.5; p=0.004) on the THI. Quality of life measures showed a significant improvement on the global subscale of the World Health Organization quality of life questionnaire (p=0.007). The SSQ indicated a significant improvement from 4.2 to 6 (p=0.004) in speech comprehension and from 3 to 5.3 (p=0.009) in spatial hearing. No significant difference was noted in the subscale qualities of hearing (6.2 to 6.9; p=0.13). The scores of the patient's on the 3 subscales were significantly lower than for the normal hearing control group, with an average speech comprehension score of 8.7 (p=0.001), an average spatial hearing of 8.6 (p<0.001), and an average quality of hearing score of 9.1 (p=0.005). Adverse events were not reported.
Poncet-Wallet et al. (2019) reported on audiological and tinnitus outcomes of cochlear implantation in adults with SSD and tinnitus. Twenty-six patients with SSD and incapacitating tinnitus (THI score > 58) underwent cochlear implantation. Masking white noise stimulation was delivered for the first month post-implantation, after which standard cochlear implant stimulation was provided. Catastrophic handicaps (grade 5, THI 78-100) were noted for 31% of participants and severe handicaps (grade 4, THI 58-76) were noted for 69% of participants. The first month of white noise stimulation provided a significant improvement in THI scores (72 ±9 to 55 ±20; p<0.05). No change was observed for the other measures at this time point. After 1 year of standard stimulation, 23 patients (92%) completed the final 13-month visit with 0% of participants reporting catastrophic handicaps, 4% reporting severe handicaps, and 26% reporting moderate handicaps (grade 3, THI 38-56), 30% reporting mild handicaps (grade 2, THI 18-36), and 39% reporting slight or no handicaps (grade 1, THI 0-16) (p<0.05). All 23 patients attending the 13-month visit reported improvement of tinnitus on at least 2 of 4 tinnitus questionnaires.

In July 2019, the FDA approved to expand the indication for the MED-EL Cochlear Implant System to include individuals aged 5 years and older with SSD or asymmetric hearing loss (AHL). According to the FDA’s summary of safety and effectiveness data, approval was based on supporting evidence from a comprehensive literature review and a clinical feasibility study conducted at the University of North Carolina at Chapel Hill under IDE# G140050 in patients treated between 2014 and 2019. In this prospective, non-blinded, repeated measures study, 40 subjects were implanted with the MED-EL CONCERT or SYNCHRONY Cochlear Implant System. Twenty patients each were enrolled into the SSD and AHL groups. All 20 patients completed testing in the SSD group. One patient withdrew from the AHL group and 1 patient had not yet completed follow-up at the time of data analysis. Patients were required to have previous experience of at least 1 month in duration with a conventional hearing aid, bone conduction device, or contralateral routing of signal device. Exclusion criteria included Meniere's disease with intractable vertigo, tinnitus as the primary concern for cochlear implantation, and severe or catastrophic score on the THI. Aided word recognition in the ear to be implanted was required to be 60% or less as measured with a 50-word CNC word list. Speech perception and localization were evaluated at baseline and at 1, 3, 6, 9, and 12 months post-operatively utilizing CNC word recognition and AzBio sentence tests. For patients in the AHL group, sound field testing was completed with a hearing aid in the contralateral ear. Quality of life measures included the SSQ, THI, and Abbreviated Profile of Hearing Aid Benefit (APHAB) scales. Primary effectiveness measures were comparisons of speech perception and localization performance between the bilateral, pre-operative, unaided/best-aided condition and the bilateral, 12-month post-operative cochlear implant + normal hearing or hearing aid condition. Study results are summarized in Table 2. Nine device- or procedure-related adverse events were reported. Most frequently reported adverse events included vertigo/dizziness/imbalance (22.5%) and unrelated infection (7.5%). The data from the is limited by its small sample size in adult subjects only. Effectiveness endpoints were not prespecified.

The FDA decision was further supported by a literature search yielding 6 publications comprising a total of 58 adults with SSD (N=50 of which implanted with MED-EL devices) and a total of 52 adults with AHL (N=37 of which implanted with MED-EL devices). The decision to expand the indication pediatric patients ages 5 and older was based on a literature search yielding 5 publications comprising a total of 26 children with SSD (N=5 of which implanted with a MED-EL device) and a total of 9 children with AHL. While the overall benefits of cochlear implants in children with SSD and AHL included improved performance in speech perception in quiet and noise, sound localization, and subjective measures of quality of life these results are limited to primarily case series with small sample sizes, heterogeneous in methodology and outcome assessment, and at high-risk of bias in self-reported measures. The FDA has required MED-EL to conduct a post-marketing study to continue to assess the safety and efficacy of the implant in a new enrollment cohort of adults and children.
<table>
<thead>
<tr>
<th>Outcome</th>
<th>SSD (n=20)</th>
<th>AHL (n=18)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Speech Perception in Quiet</td>
<td>Baseline, Unaided</td>
<td>Baseline, Unaided</td>
</tr>
<tr>
<td>Implant Ear CNC, Mean (SD) Range</td>
<td>3.5 (6.68); 0 to 22</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contralateral Ear CNC, Mean (SD) Range</td>
<td>99.3 (2.27); 90 to 100</td>
<td>99.8 (0.62); 98 to 100</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Soundfield, Binaural AzBio, Mean (SD) Range</td>
<td>99.0 (1.56); 95 to 100</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Localization Performance</td>
<td>Baseline, Unaided</td>
<td>Baseline, Unaided</td>
</tr>
<tr>
<td>Mean RMS Error (SD) Range</td>
<td>66.5 (20.47); 42.9 to 109.1</td>
<td>77.2 (18.89); 45.6 to 106.5</td>
</tr>
<tr>
<td>Quality of Life</td>
<td>SSQ (Speech)</td>
<td>APHAB (Global)</td>
</tr>
<tr>
<td>SSD (N=20)</td>
<td>3.7 (1.34); 0.6 to 7.2</td>
<td>EC: 31.6 (21.06); 2.8 to 81.0</td>
</tr>
<tr>
<td>12-mo: Mean (SD); Range</td>
<td>7.1 (0.99); 6.5 to 8.9</td>
<td>8.7 (6.15); 1.0 to 24.8</td>
</tr>
<tr>
<td></td>
<td>5.4 to 8.9</td>
<td>70.1 (17.32); 39.3 to 95.0</td>
</tr>
<tr>
<td></td>
<td></td>
<td>25.2 (11.95); 10.2 to 56.2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>RV: 47.5 (21.96); 18.7 to 87.0</td>
</tr>
<tr>
<td></td>
<td></td>
<td>19.7 (12.43); 2.8 to 41.7</td>
</tr>
</tbody>
</table>

Reproduction without authorization from Blue Shield of California is prohibited
AHL: asymmetric hearing loss; APHAB: Abbreviated Profile of Hearing Aid Benefit; AV: Aversiveness subscale; BCHA: bone conduction hearing aid; BN: Background Noise subscale; CI: cochlear implant; CNC: consonant-nucleus-consonant; EC: Ease of Communication subscale; NA: not applicable; NR: not reported; RMS: root mean square; RV: Reverberation subscale; SD: standard deviation; SSD: single-sided deafness; SSQ: Speech, Spatial, and Qualities of Hearing Scale; THI: Tinnitus Handicap Inventory.

Case Series
Several individual studies have reported on longer-term outcomes for cochlear implantation for SSDs since the publication of the van Zon et al. (2015) systematic review.

The longest follow-up was reported by Mertens et al. (2015) in a case series with structured interviews, which included 23 individuals who received cochlear implants for SSD with tinnitus.37, Eligible patients had either SSD or asymmetric hearing loss and ipsilateral tinnitus. Subjects had a mean 8 years of experience with their cochlear implant (range, 3-10 years). Tinnitus symptoms were assessed by structured interview, VAS, and the Tinnitus Questionnaire (a validated scale). Patients demonstrated improvements in VAS scores from baseline (mean score, 8) to 1 month (mean score: 4; p<0.01 vs. baseline) and to 3 months (mean score, 3; p<0.01 vs. baseline) after the first fitting. Tinnitus Questionnaire scores improved from baseline to 3 months after fitting (55 vs. 31, p<0.05) and were stable for the remainder of follow-up.

Rahne et al. (2016) reported on a retrospective review of 4 children and 17 adults with SSD treated with cochlear implants and followed for 12 months.38, Sound localization with aided hearing improved from preimplantation for all individuals. The speech recognition threshold in noise (signal-to-noise) ratio improved from -1.95 dB (cochlear implant off, SD, 2.7 dB) to -4.0 dB after 3 months (SD, 1.3 dB; p<0.05), with continued improvements through 6 months.

Cochlear Implant for Tinnitus Relief in Patients With Unilateral Deafness
Based on observations about tinnitus improvement with cochlear implants, several studies have reported on improvements in tinnitus after cochlear implantation in individuals with unilateral hearing loss. For example, in the meta-analysis by Vlastarakos et al. (2014), tinnitus improved in most patients (95%).39
Ramos Macias et al. (2015) reported on results of a prospective multicenter study with repeated measures related to tinnitus, hearing, and quality of life, among 16 individuals with unilateral hearing loss and severe tinnitus who underwent cochlear implantation. All patients had a severe tinnitus handicap (THI score ≥58%). Eight (62%) of the 13 patients who completed the 6-month follow-up visit reported a lower tinnitus handicap on the THI score. Perceived loudness/annoyingness of the tinnitus was evaluated with a 10-point VAS. Tinnitus loudness decreased from 8.4 preoperatively to 2.6 at the 6-month follow-up.

Tavora-Vieira et al. (2013) reported on results of a prospective case series that included 9 postlingually deaf subjects with unilateral hearing loss, with or without tinnitus in the ipsilateral ear, with functional hearing in the contralateral ear, who underwent cochlear implantation. Speech perception was improved for all subjects in the “cochlear implant on” state compared with the “cochlear implant off” state, and subjects with tinnitus generally reported improvement.

Section Summary: Cochlear Implantation for Unilateral Sensorineural Hearing Loss
The available evidence for the use of cochlear implants in improving outcomes for patients with unilateral hearing loss, with or without tinnitus, is limited by small sample sizes and heterogeneity in evaluation protocols and outcome measurements. A small feasibility study in adults with SSD or AHL demonstrated improvements in sound perception, sound localization, and subjective measures of quality of life compared to baseline conditions. However, studies assessing outcomes compared to best-aided hearing controls across multiple time points are lacking. An ongoing post-marketing study in adults and children may further elucidate outcomes.

Hybrid Cochlear Implantation for Individuals With High-Frequency Sensorineural Hearing Loss With Preserved Low-Frequency Hearing

Clinical Context and Therapy Purpose
The purpose of a hybrid cochlear implant that includes a hearing aid integrated into the external sound processor of the cochlear implant is to provide a treatment option that is an alternative to or an improvement on existing therapies, such as best-aided hearing, in patients with high-frequency sensorineural hearing loss with preserved low-frequency hearing.

The question addressed in this evidence review is: Does the use of a cochlear implant improve the net health outcome for patients with unilateral or bilateral hearing loss?

The following PICO was used to select literature to inform this review.

Patients
The relevant population of interest is individuals with high-frequency sensorineural hearing loss with preserved low-frequency hearing.

Interventions
The therapy being considered is a hybrid cochlear implant that includes a hearing aid integrated into the external sound processor of the cochlear implant.

Comparators
Comparators of interest include best-aided hearing.

Outcomes
The general outcomes of interest are symptoms, functional outcomes, treatment-related mortality, and treatment-related morbidity.
Study Selection Criteria

Methodologically credible studies were selected using the following principles:

a. To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;

b. In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies;

c. To assess longer-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.

d. Studies with duplicative or overlapping populations were excluded.

Nonrandomized Trials

A concern about traditional cochlear implants is that the implantation process typically destroys any residual hearing, particularly for hearing in the low-frequency ranges. Newer devices have used a shorter cochlear electrode in combination with a hearing aid-like amplification device to mitigate the damage to the cochlea and preserve residual hearing.

In September 2016, the FDA approved the MED-EL Cochlear Implant with Combined Electrical Stimulation and Acoustic Amplification System (EAS) for partially deaf individuals aged 18 years and older who have residual hearing sensitivity in the low frequencies sloping to severe/profound sensorineural hearing loss in the mid- to high-frequencies, and who receive minimal benefit from conventional acoustic amplification. Final outcomes were reported in 2018 by Pillsbury et al. Sixty-seven of 73 subjects (92%) completed outcome measures at 3, 6, and 12 months postactivation. A 30 dB or less low-frequency pure-tone average shift was experienced by 79% and 97% were able to use the acoustic unit at 12 months postactivation. In the EAS condition, 94% of subjects performed similarly or demonstrated improvement (85%) compared to preoperative performance on City University of New York sentences in noise at 12 months. Ninety-seven percent of subjects performed similarly or improved (85%) on CNC words in quiet. Improvements in speech perception scores were statistically significant (p<0.001). The APHAB was administered preoperatively and at 12 months postactivation; 60 subjects completed the APHAB assessment at each time point. The mean score on the APHAB Global Scale improved by 30.2%, demonstrating a significant reduction in perceived disability (p<0.001). Thirty-five device-related adverse events were reported for 29 of 73 subjects (39.7%). The most frequently observed adverse event was profound/total loss of residual hearing, which occurred in 8 of 73 subjects (11.0%).

In March 2014, the FDA approved the Nucleus Hybrid L24 Cochlear Implant System for use through the premarket approval process. According to the FDA’s summary of safety and effectiveness data, approval was based on 2 clinical studies conducted outside of the United States and a pivotal study of the Hybrid L24 device conducted under investigational device exemption.

The pivotal trial was a prospective, multicenter, single-arm, nonrandomized, nonblinded, repeated measures clinical study among 50 subjects ≥ 18 years of age at 10 U.S. sites. Results were reported in FDA documentation and peer-reviewed form by Roland et al. (2016). Eligible patients were selected on the basis of having severe high-frequency sensorineural hearing loss (≥70 dB hearing level averaged over 2000, 3000, and 4000 Hz) with relatively good low-frequency hearing (≤60 dB hearing level averaged over 125, 250, and 500 Hz) in the ear selected for implantation. The performance was compared pre- and post-implantation within each subject; outcomes were measured at 3, 6, and 12 months postoperatively. The trial tested 2 coprimary efficacy hypotheses: (1) that outcomes on CNC, a measure of word recognition, and (2) AzBio sentences in noise presented through the hybrid implant system would be better at 6 months post-implantation than preoperative performance using a hearing aid.

All 50 subjects enrolled underwent device implantation and activation. One subject had the device explanted and replaced with a standard cochlear implant between the 3- and 6-month follow-up visit due to profound loss of low-frequency hearing; an additional subject was
explanted before the 12-month follow-up visit, and 2 other subjects were explanted after 12 months. For the 2 primary effectiveness endpoints (CNC word recognition score, AzBio sentence-in-noise score), there were significant within-subject improvements from baseline to 6-month follow-up. Mean improvement in CNC word score was 35.8% (95% CI, 27.8% to 43.6%); for AzBio score, mean improvement was 32.0% (95% CI, 23.6% to 40.4%). Ninety-six percent of subjects performed equal or better on speech in quiet and 90% performed equal or better in noise. For safety outcomes, 65 adverse events were reported, most commonly profound/total loss of hearing (occurring in 44% of subjects) with at least 1 adverse event occurring in 34 subjects (68%).

Five-year outcomes for the pivotal trial were reported by Roland et al. (2018).44 Thirty-two out of 50 subjects (64%) enrolled in the postapproval study. Out of the 18 subjects who did not participate, 6 had been explanted and reimplanted with a long electrode array, 2 discontinued for unrelated medical reasons, 2 withdrew for other reasons, 4 declined to continue follow-up evaluations, and 4 chose not to participate in the postapproval study. At 5 years postactivation, 94% of subjects had measurable hearing and 72% continued to use electric-acoustic stimulation with functional hearing in the implanted ear, and 6% had a total loss. Changes from pre-operative hearing to 6 months were statistically significant (p<0.001), but changes 6 months through 5 years postactivation were not statistically different (p>0.05). Acoustic component amplification was utilized by 84% and 81% of patients at 12 and 3 years postactivation, respectively. Mean CNC word recognition in quiet scores were significantly improved over the preoperative condition at each postactivation interval (p<0.001). However, mean scores did not significantly differ after 12 months postactivation. At 5 years postactivation, 94% performed the same or better in unilateral CNC word scores, whereas 6% demonstrated a decline in performance. For bilateral CNC word scores, 97% performed the same or better, whereas 1 subject showed a decline in performance. The Speech, Spatial, and Qualities of Hearing Questionnaire (SSQ) was implemented to measure subjective implant satisfaction and benefit. Scores significantly improved and remained stable through all postactivation intervals (p<0.001).

Lenarz et al. (2013) reported on results of a prospective multicenter European study evaluating the Nucleus Hybrid L24 system.45 The study enrolled 66 adults with bilateral severe-to-profound high-frequency hearing loss. At 1 year postoperatively, 65% of subjects had significant gains in speech recognition in quiet, and 73% had significant gains in noisy environments. Compared with the cochlear implant hearing alone, residual hearing significantly increased speech recognition scores.

Hearing Benefit With Shorter Cochlear Array
The Nucleus Hybrid L24 system was designed with a shorter cochlear implant with the intent of preserving low-frequency hearing. A relevant question is whether a shorter implant is associated with differences in outcomes, although studies addressing this question do not directly provide evidence about hybrid implants themselves.

Santa Maria et al. (2014) published a meta-analysis of hearing outcomes after various types of hearing preservation cochlear implantation, which included implantation of hybrid devices, cochlear implantation with surgical techniques designed to preserve hearing, and the use of postoperative systemic steroids.46 Reviewers included 24 studies, but only 2 focused specifically on a hybrid cochlear implant system, and no specific benefit from a hybrid system was reported.

Causon et al. (2015) evaluated factors associated with cochlear implant outcomes in a meta-analysis of articles published from 2003 to 2013, which reported on pure-tone audiometry measurements pre- and post-cochlear implantation.47 Twelve studies with available audiometric data (total N=200 patients) were included. Reviewers standardized degree of hearing preservation after cochlear implant using the HEARING consensus statement formula. This formula calculates a percentage of hearing preservation at a specific frequency band, which is scaled to the preoperative audiogram by dividing the change in hearing by the difference between the maximum measurable threshold and the preoperative hearing threshold. The
association of a variety of patient- and surgery-related factors, including insertion depth, and improvement in low-frequency hearing were evaluated. In this analysis, insertion depth was not significantly associated with low-frequency residual hearing.

Since the publication of the Santa Maria and Causon studies, which evaluated factors associated with cochlear implant outcomes, additional studies have attempted to evaluate whether shorter cochlear arrays are more likely to preserve hearing.

Gantz et al. (2016) published outcomes from a multicenter, longitudinal study evaluating outcomes with the Nucleus Hybrid S8 featuring a shorter cochlear array.48 Eighty-seven subjects received an implant. At 12 months postactivation, 5 subjects had total hearing loss, whereas functional hearing was maintained by 80%. CNC word scores demonstrated 82.5% of subjects had experienced a significant improvement in the hybrid condition. Improvement in speech understanding in noise were demonstrated in 55% of subjects. Fourteen patients requested implant explantation due to various reasons for dissatisfaction with the device. These patients were re-implanted with a standard length Nucleus Freedom cochlear implant. CNC scores prior to loss of residual hearing were missing for 6 subjects. CNC scores following re-implantation were missing for 2 additional subjects. Similar or better CNC scores following re-implantation were observed in 5/6 remaining subjects.

Section Summary: Hybrid Cochlear Implantation
Prospective and retrospective studies using a single-arm, within-subjects comparison pre- and postintervention have suggested that a hybrid cochlear implant system is associated with improvements in hearing of speech in quiet and noise. For patients who have high-frequency hearing loss but preserved low-frequency hearing, the available evidence has suggested that a hybrid cochlear implant improves speech recognition better than a hearing aid alone. Some studies have suggested that a shorter cochlear implant insertion depth may be associated with preserved residual low-frequency hearing, although there is uncertainty about the potential need for reoperation following hybrid cochlear implantation if there is a loss of residual hearing. Studies reporting on long-term outcomes and results of re-implantation are lacking.

Summary of Evidence
For individuals who have bilateral sensorineural hearing loss who receive the cochlear implant(s), the evidence includes randomized controlled trials (RCTs) and multiple systematic reviews and technology assessments. Relevant outcomes are symptoms, functional outcomes, and treatment-related mortality and morbidity. The available studies have reported improvements in speech reception and quality of life measures. Although the available RCTs and other studies measured heterogeneous outcomes and included varying patient populations, the findings are consistent across multiple studies and settings. In addition to consistent improvement in speech reception (especially in noise), studies showed improvements in sound localization with bilateral devices. Studies have also suggested that earlier implantation may be preferred. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have unilateral sensorineural hearing loss who receive the cochlear implant(s), the evidence includes a feasibility study, prospective and retrospective studies reporting within-subjects comparisons, and systematic reviews of observational studies. Relevant outcomes are symptoms, functional outcomes, and treatment-related mortality and morbidity. Given the natural history of hearing loss, pre- and postimplantation comparisons may be appropriate for objectively measured outcomes. However, the available evidence for the use of cochlear implants in improving outcomes for patients with unilateral hearing loss, with or without tinnitus, is limited by small sample sizes and heterogeneity in evaluation protocols and outcome measurements. A small feasibility study in adults with single-sided deafness or asymmetric hearing loss demonstrated improvements in sound perception, sound localization, and subjective measures of quality of life compared to baseline conditions. However, studies assessing outcomes compared to best-aided hearing controls across multiple time points are
lacking. An ongoing post-marketing study in adults and children may further elucidate outcomes. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have a high-frequency sensorineural hearing loss with preserved low-frequency hearing who receive a hybrid cochlear implant that includes a hearing aid integrated into the external sound processor of the cochlear implant, the evidence includes prospective and retrospective studies using single-arm, within-subject comparison pre- and postintervention and systematic reviews. Relevant outcomes are symptoms, functional outcomes, and treatment-related mortality and morbidity. The available evidence has suggested that a hybrid cochlear implant system is associated with improvements in hearing of speech in quiet and noise. The available evidence has also suggested that a hybrid cochlear implant improves speech recognition better than a hearing aid alone. Some studies have suggested that a shorter cochlear implant insertion depth may be associated with preserved residual low-frequency hearing, although there is uncertainty about the potential need for reoperation after hybrid cochlear implantation if there is a loss of residual hearing. Studies reporting on long-term outcomes and results of re-implantation are lacking. The evidence is insufficient to determine the effects of the technology on health outcomes.

**Supplemental Information**

**Clinical Input From Physician Specialty Societies and Academic Medical Centers**

While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

**2016 Input**

In response to requests from Blue Cross Blue Shield Association, input was received from 2 specialty societies, 1 of which provided 4 responses and 1 of which provided 3 responses, and 3 academic medical centers in 2016. Input focused on the use of hybrid cochlear implants. Input was consistent that the use of a hybrid cochlear implant/hearing aid device that includes the hearing aid integrated into the external sound processor of the cochlear implant improves outcomes for patients with high-frequency hearing loss but preserved low-frequency hearing.

**2010 Input**

In response to requests from Blue Cross Blue Shield Association, input was received from 2 physician specialty societies and 4 academic medical centers in 2010. Also, unsolicited input was received from a specialty society. Most providing input supported the use of cochlear implants in infants younger than 12 months of age; many supporting this use noted that there are major issues when determining the hearing level in infants of this age group, and others commented that use could be considered in these young infants only in certain situations. Those providing input were divided on the medical necessity of upgrading functioning external systems/some agreed, and others did not.

**Practice Guidelines and Position Statements**

**American Academy of Otolaryngology - Head and Neck Surgery Foundation**

In 2014, the American Academy of Otolaryngology - Head and Neck Surgery Foundation has a position statement on cochlear implants that was revised. The Foundation “…considers unilateral and bilateral cochlear implantation as appropriate treatment for adults and children with severe to profound hearing loss. Based on extensive literature demonstrating that clinically selected adults and children can perform significantly better with two cochlear implants [rather] than one, bilateral cochlear implantation is accepted medical practice.”
Agency for Health Care Research and Quality
In 2011, a technology assessment for the Agency for Health Care Research and Quality assessed the effectiveness of cochlear implants in adults. The assessment conclusions are noted within the body of this evidence review.

National Institute for Health and Care Excellence
In 2019, the National Institute for Health and Care Excellence (NICE) released a technology appraisal guidance on cochlear implants for children and adults with severe-to-profound deafness. The guidance included the following updated recommendations:

1.1 "Unilateral cochlear implantation is recommended as an option for people with severe to profound deafness who do not receive adequate benefit from acoustic hearing aids, as defined in 1.5.
1.2 Simultaneous bilateral cochlear implantation is recommended as an option for the following groups of people with severe to profound deafness who do not receive adequate benefit from acoustic hearing aids.
   a. Children
   b. Adults who are blind or who have other disabilities that increase their reliance on auditory stimuli as a primary sensory mechanism for spatial awareness.
1.3 Sequential bilateral cochlear implantation is not recommended as an option for people with severe to profound deafness.
1.5 For the purposes of this guidance, severe to profound deafness is defined as hearing only sounds that are louder than 80 dB HL [hearing level] at 2 or more frequencies bilaterally (500 Hz, 1 kHz, 2 kHz, 3 kHz, 4 kHz) without acoustic hearing aids. Adequate benefit from acoustic hearing aids is defined for this guidance as:
   a. for adults, a phoneme score of 50% or greater on the Arthur Boothroyd word test presented at 70 dBA
   b. for children, speech, language and listening skills appropriate to age, developmental stage, and cognitive ability.
1.6 Cochlear implantation should be considered for children and adults only after an assessment by a multidisciplinary team. As part of the assessment, children and adults should also have had a valid trial of an acoustic hearing aid for at least 3 months (unless contraindicated or inappropriate).
1.7 Cochlear implantation should be considered for adults only after an assessment by a multidisciplinary team. As part of the assessment, implant candidates should also have had a valid trial of an acoustic hearing aid for at least 3 months (unless contraindicated or inappropriate)."

National Institutes of Health
Cochlear implants are recognized as an effective treatment of sensorineural deafness, as noted in a 1995 National Institutes of Health Consensus Development conference, which offered the following conclusions:

"Cochlear implantation has a profound impact on hearing and speech perception in postlingually deafened adults.

"Prelingually deafened adults generally show little improvement in speech perception scores after cochlear implantation, but many of these individuals derive satisfaction from hearing environmental sounds and continue to use their implants." However, improvements in other basic benefits, such as sound awareness, may meet safety needs.

"...training and educational intervention are fundamental for optimal postimplant benefit." The conference offered the following conclusions regarding cochlear implantation in children: "Cochlear implantation outcomes are more variable in children. Nonetheless, gradual, steady improvement in speech perception, speech production, and language does occur."
Cochlear implants in children under 2 years old are complicated by the inability to perform a detailed assessment of hearing and functional communication. However, “a younger age of implantation may limit the negative consequences of auditory deprivation and may allow more efficient acquisition of speech and language.” Some children with a postmeningitis hearing loss under the age of 2 years have received an implant due to “the risk of new bone formation associated with meningitis, which might preclude implantation at a later date.”

**U.S. Preventive Services Task Force Recommendations**
Not applicable.

**Medicare National Coverage**
Existing national coverage states:

“...cochlear implantation may be covered for treatment of bilateral pre- or post-linguistic, sensorineural, moderate-to-profound hearing loss in individuals who demonstrate limited benefit from amplification.... [which is] defined by test scores of less than or equal to 40% correct in the best-aided listening condition on tape recorded tests of open-set sentence cognition.”

Coverage for cochlear implants may also be provided when the patient has “...hearing test scores of greater than 40% and less than or equal to 60% only when the provider is participating in, and patients are enrolled in, either an FDA-approved category B investigational device exemption clinical trial ..., or a prospective, controlled comparative trial approved by CMS...”

**Ongoing and Unpublished Clinical Trials**
Some currently unpublished trials that might influence this review are listed in Table 3.

### Table 3. Summary of Key Trials

<table>
<thead>
<tr>
<th>NCTNo.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ongoing</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT02941627a</td>
<td>The Neuro 2Ti Cochlear Implant System Efficacy and Safety in Adults</td>
<td>55</td>
<td>Jul 2018 (unknown)</td>
</tr>
<tr>
<td>NCT03007472a</td>
<td>Clinical Evaluation of the Cochlear Nucleus(R) CI532 Cochlear Implant in Adults</td>
<td>100</td>
<td>Jul 2019 (ongoing)</td>
</tr>
<tr>
<td>NCT02532972</td>
<td>Cochlear Implantation for Treatment of Single-sided Deafness</td>
<td>11</td>
<td>Nov 2019 (ongoing)</td>
</tr>
<tr>
<td>NCT02075229</td>
<td>A Proposal to Evaluate Revised Indications for Cochlear Implant Candidacy for the Adult CMS Population</td>
<td>90</td>
<td>Jun 2020 (recruiting)</td>
</tr>
<tr>
<td>NCT02203305a</td>
<td>Cochlear Implantation in Cases of Single-Sided Deafness</td>
<td>50</td>
<td>Dec 2020 (ongoing)</td>
</tr>
<tr>
<td>NCT03929809</td>
<td>Iowa Cochlear Implant Clinical Research Center Study of SSD Using Med-El Cochlear Implants</td>
<td>10</td>
<td>May 2021 (recruiting)</td>
</tr>
<tr>
<td>Unpublished</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT02105441</td>
<td>Cochlear Implantation Among Adults and Older Children With Unilateral or Asymmetric Hearing Loss</td>
<td>40</td>
<td>Mar 2018 (completed)</td>
</tr>
</tbody>
</table>

NCT: national clinical trial.
a Industry-sponsored or partially sponsored.
References


**Documentation for Clinical Review**

Please provide the following documentation (if/when requested):
- History and physical and/or consultation notes including:
  - Previous treatment plan and response
  - Progress notes for the past six months
  - Hearing test results, if applicable
  - Cochlear implant manufacturer, model, and invoice

For Upgrade or Replacement:
- Manufacturer warranty information, description of non-function or failure, repair log, and reason component or system cannot be repaired (if applicable)
- Treating physician’s progress notes indicating:
  - Type of present device and length of usage
  - Patient’s current condition and change in condition (if applicable)
  - Inadequacies of the present system or component
  - Patient’s capabilities with his/her current implant and of the requested upgrade or component (if applicable)
  - How the upgrade or component is expected to provide clinically significant improvement (if applicable)

Post Service
- Operative/procedures notes (if applicable)

**Coding**

This Policy relates only to the services or supplies described herein. Benefits may vary according to product design; therefore, contract language should be reviewed before applying the terms of the Policy. Inclusion or exclusion of codes does not constitute or imply member coverage or provider reimbursement.

**MN/IE**
The following services may be considered medically necessary in certain instances and investigational in others. Services may be considered medically necessary when policy criteria are met. Services may be considered investigational when the policy criteria are not met or when the code describes application of a product in the position statement that is investigational.

<table>
<thead>
<tr>
<th>Type</th>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT®</td>
<td>69930</td>
<td>Cochlear device implantation, with or without mastoidectomy</td>
</tr>
<tr>
<td>Type</td>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>-------------</td>
<td>--------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td></td>
<td>92507</td>
<td>Treatment of speech, language, voice, communication, and/or auditory processing disorder; individual</td>
</tr>
<tr>
<td></td>
<td>92601</td>
<td>Diagnostic analysis of cochlear implant, patient younger than 7 years of age; with programming</td>
</tr>
<tr>
<td></td>
<td>92602</td>
<td>Diagnostic analysis of cochlear implant, patient younger than 7 years of age; subsequent reprogramming</td>
</tr>
<tr>
<td></td>
<td>92603</td>
<td>Diagnostic analysis of cochlear implant, age 7 years or older; with programming</td>
</tr>
<tr>
<td></td>
<td>92604</td>
<td>Diagnostic analysis of cochlear implant, age 7 years or older; subsequent reprogramming</td>
</tr>
<tr>
<td></td>
<td>92605</td>
<td>Evaluation for prescription of non-speech-generating augmentative and alternative communication device, face-to-face with the patient; first hour</td>
</tr>
<tr>
<td></td>
<td>92606</td>
<td>Therapeutic service(s) for the use of non-speech-generating device, including programming and modification</td>
</tr>
<tr>
<td></td>
<td>92607</td>
<td>Evaluation for prescription for speech-generating augmentative and alternative communication device, face-to-face with the patient; first hour</td>
</tr>
<tr>
<td></td>
<td>92608</td>
<td>Evaluation for prescription for speech-generating augmentative and alternative communication device, face-to-face with the patient; each additional 30 minutes (List separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td></td>
<td>92609</td>
<td>Therapeutic services for the use of speech-generating device, including programming and modification</td>
</tr>
<tr>
<td></td>
<td>92618</td>
<td>Evaluation for prescription of non-speech-generating augmentative and alternative communication device, face-to-face with the patient; each additional 30 minutes (List separately in addition to code for primary procedure)</td>
</tr>
</tbody>
</table>

**HCPCS**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>L8614</td>
<td>Cochlear device, includes all internal and external components</td>
</tr>
<tr>
<td>L8615</td>
<td>Headset/headpiece for use with cochlear implant device, replacement</td>
</tr>
<tr>
<td>L8616</td>
<td>Microphone for use with cochlear implant device, replacement</td>
</tr>
<tr>
<td>L8617</td>
<td>Transmitter coil for use with cochlear implant device, replacement</td>
</tr>
<tr>
<td>L8618</td>
<td>Transmitter cable for use with cochlear implant device or auditory osseointegrated device replacement</td>
</tr>
<tr>
<td>L8619</td>
<td>Cochlear implant, external speech processor and controller, integrated system, replacement</td>
</tr>
<tr>
<td>L8621</td>
<td>Zinc air battery for use with cochlear implant device and auditory osseointegrated sound processors, replacement, each</td>
</tr>
<tr>
<td>L8622</td>
<td>Alkaline battery for use with cochlear implant device, any size, replacement, each</td>
</tr>
<tr>
<td>L8623</td>
<td>Lithium ion battery for use with cochlear implant device speech processor, other than ear level, replacement, each</td>
</tr>
<tr>
<td>L8624</td>
<td>Lithium ion battery for use with cochlear implant or auditory osseointegrated device speech processor ear level replacement each</td>
</tr>
<tr>
<td>L8625</td>
<td>External recharging system for battery for use with cochlear implant or auditory osseointegrated device replacement only each</td>
</tr>
<tr>
<td>L8627</td>
<td>Cochlear implant, external speech processor, component, replacement</td>
</tr>
<tr>
<td>L8628</td>
<td>Cochlear implant, external controller component, replacement</td>
</tr>
<tr>
<td>L8629</td>
<td>Transmitting coil and cable, integrated, for use with cochlear implant device, replacement</td>
</tr>
</tbody>
</table>
### Policy History

This section provides a chronological history of the activities, updates and changes that have occurred with this Medical Policy.

<table>
<thead>
<tr>
<th>Effective Date</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>03/05/1986</td>
<td>BCBSA Medical Policy adoption</td>
</tr>
<tr>
<td>02/28/1991</td>
<td>Policy Revision</td>
</tr>
<tr>
<td>07/26/2001</td>
<td>BCBSA Medical Policy adoption</td>
</tr>
<tr>
<td>12/01/2006</td>
<td>BCBSA Medical Policy adoption</td>
</tr>
<tr>
<td>04/05/2007</td>
<td>BCBSA Medical Policy adoption</td>
</tr>
<tr>
<td>12/01/2008</td>
<td>Adopted BCBSA policy “Auditory Brainstem Implants, combined Cochlear Implants and Auditory Brainstem Implants policies, adopted BCBSA policies statements, included benefit allowances and exclusions, policy title change, codes revised.</td>
</tr>
<tr>
<td>01/15/2010</td>
<td>Coding Update</td>
</tr>
<tr>
<td>10/07/2011</td>
<td>Policy revision without position change</td>
</tr>
<tr>
<td>10/05/2012</td>
<td>Policy revision for clarification of replacement/upgrade language</td>
</tr>
<tr>
<td>07/31/2015</td>
<td>Title change from Cochlear and Auditory Brainstem Implant Policy revision with position change Policy split into two policies-Cochlear Implant and Auditory Brainstem Implant</td>
</tr>
<tr>
<td>02/01/2016</td>
<td>Coding update</td>
</tr>
<tr>
<td>09/01/2016</td>
<td>Policy revision with position change</td>
</tr>
<tr>
<td>04/01/2017</td>
<td>Policy revision without position change</td>
</tr>
<tr>
<td>01/01/2018</td>
<td>Coding update</td>
</tr>
<tr>
<td>04/01/2018</td>
<td>Policy revision without position change</td>
</tr>
<tr>
<td>04/01/2019</td>
<td>Policy revision without position change</td>
</tr>
<tr>
<td>05/01/2020</td>
<td>Annual review. Policy statement, guidelines, and literature updated.</td>
</tr>
</tbody>
</table>

### Definitions of Decision Determinations

**Medically Necessary:** Services that are Medically Necessary include only those which have been established as safe and effective, are furnished under generally accepted professional standards to treat illness, injury or medical condition, and which, as determined by Blue Shield, are: (a) consistent with Blue Shield medical policy; (b) consistent with the symptoms or diagnosis; (c) not furnished primarily for the convenience of the patient, the attending Physician or other provider; (d) furnished at the most appropriate level which can be provided safely and effectively to the patient; and (e) not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of the Member’s illness, injury, or disease.

**Investigational/Experimental:** A treatment, procedure, or drug is investigational when it has not been recognized as safe and effective for use in treating the particular condition in accordance with generally accepted professional medical standards. This includes services where approval by the federal or state governmental is required prior to use, but has not yet been granted.

**Split Evaluation:** Blue Shield of California/Blue Shield of California Life & Health Insurance Company (Blue Shield) policy review can result in a split evaluation, where a treatment, procedure, or drug will be considered to be investigational for certain indications or conditions, but will be deemed safe and effective for other indications or conditions, and therefore potentially medically necessary in those instances.
Prior Authorization Requirements (as applicable to your plan)

Within five days before the actual date of service, the provider must confirm with Blue Shield that the member's health plan coverage is still in effect. Blue Shield reserves the right to revoke an authorization prior to services being rendered based on cancellation of the member's eligibility. Final determination of benefits will be made after review of the claim for limitations or exclusions.

Questions regarding the applicability of this policy should be directed to the Prior Authorization Department at (800) 541-6652, or the Transplant Case Management Department at (800) 637-2066 ext. 3507708 or visit the provider portal at www.blueshieldca.com/provider.

Disclaimer: This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. Blue Shield of California may consider published peer-reviewed scientific literature, national guidelines, and local standards of practice in developing its medical policy. Federal and state law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over medical policy and must be considered first in determining covered services. Member contracts may differ in their benefits. Blue Shield reserves the right to review and update policies as appropriate.